Scott Baver, PhD

Title: Head of Medical Affairs

Organization: ITF Therapeutics

2024 FUTURES – Therapies to Preserve and Protect Muscle

Presentations covering therapies aiming to preserve and protect muscle in Duchenne, including anti-inflammatory agents, muscle stabilizers, and other mechanisms with relevant updates from companies in the space.

 

Karyn Koladicz, MD

Executive Medical Director for Medical Affairs, Neurology PTC Therapeutics

Lianna Orlando, PhD

Senior Director of Research

CureDuchenne

Abby Bronson

Vice President, Patient Advocacy & External Innovation

Edgewise Therapeutics

Stanley Iyadurai, MD, PhD

Sr VP Medical Affairs and Drug Discovery

Catalyst

Scott Baver, PhD

Head of Medical Affairs

ITF Therapeutics

Mark Awadalla

Vice President of Clinical Operations

Capricor